| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.
|
Nat Med
|
2003
|
9.75
|
|
2
|
Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection.
|
J Exp Med
|
2008
|
5.94
|
|
3
|
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
|
J Acquir Immune Defic Syndr
|
2007
|
4.67
|
|
4
|
HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir.
|
J Clin Invest
|
2005
|
3.62
|
|
5
|
Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.
|
AIDS
|
2010
|
3.26
|
|
6
|
Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals.
|
Proc Natl Acad Sci U S A
|
2005
|
2.80
|
|
7
|
Persistent HIV RNA shedding in semen despite effective antiretroviral therapy.
|
AIDS
|
2009
|
2.77
|
|
8
|
Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy.
|
J Infect Dis
|
2011
|
2.40
|
|
9
|
Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells.
|
J Virol
|
2007
|
2.03
|
|
10
|
Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily.
|
J Exp Med
|
2004
|
2.00
|
|
11
|
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.
|
J Acquir Immune Defic Syndr
|
2009
|
1.83
|
|
12
|
Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection.
|
J Exp Med
|
2006
|
1.72
|
|
13
|
CD25+ regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8+ T cells in vitro.
|
AIDS Res Hum Retroviruses
|
2007
|
1.64
|
|
14
|
HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression.
|
Eur J Immunol
|
2010
|
1.60
|
|
15
|
Disproportionately high semen shedding of HIV is associated with compartmentalized cytomegalovirus reactivation.
|
J Infect Dis
|
2005
|
1.58
|
|
16
|
Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients.
|
AIDS
|
2007
|
1.47
|
|
17
|
Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy.
|
J Infect Dis
|
2002
|
1.44
|
|
18
|
Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer cells from HIV-infected viremic individuals.
|
PLoS Pathog
|
2008
|
1.44
|
|
19
|
Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy.
|
AIDS
|
2011
|
1.22
|
|
20
|
Relationship between the frequency of HIV-specific CD8+ T cells and the level of CD38+CD8+ T cells in untreated HIV-infected individuals.
|
Proc Natl Acad Sci U S A
|
2004
|
1.21
|
|
21
|
Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation.
|
J Immunol
|
2013
|
1.18
|
|
22
|
Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily.
|
J Exp Med
|
2004
|
1.18
|
|
23
|
Effect of antiretroviral therapy on HIV reservoirs in elite controllers.
|
J Infect Dis
|
2013
|
1.15
|
|
24
|
Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57.
|
J Virol
|
2011
|
1.14
|
|
25
|
HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates.
|
J Clin Invest
|
2012
|
1.14
|
|
26
|
Coinfection with herpes simplex virus type 2 is associated with reduced HIV-specific T cell responses and systemic immune activation.
|
J Infect Dis
|
2008
|
1.11
|
|
27
|
Antigen-independent induction of Tim-3 expression on human T cells by the common γ-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway.
|
J Immunol
|
2012
|
1.10
|
|
28
|
A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune.
|
AIDS
|
2011
|
1.10
|
|
29
|
HIV-specific CD8+ lymphocytes in semen are not associated with reduced HIV shedding.
|
J Immunol
|
2005
|
1.09
|
|
30
|
Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection.
|
PLoS One
|
2012
|
1.07
|
|
31
|
The role of the p38 mitogen-activated protein kinase, extracellular signal-regulated kinase, and phosphoinositide-3-OH kinase signal transduction pathways in CD40 ligand-induced dendritic cell activation and expansion of virus-specific CD8+ T cell memory responses.
|
J Immunol
|
2004
|
1.03
|
|
32
|
Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals.
|
AIDS
|
2011
|
1.02
|
|
33
|
Human immunodeficiency virus type 1 escapes from interleukin-2-producing CD4+ T-cell responses without high-frequency fixation of mutations.
|
J Virol
|
2009
|
0.99
|
|
34
|
HIV-1 gp120 induces TLR2- and TLR4-mediated innate immune activation in human female genital epithelium.
|
J Immunol
|
2013
|
0.96
|
|
35
|
Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals.
|
J Immunol
|
2003
|
0.95
|
|
36
|
HIV-specific T-cells accumulate in the liver in HCV/HIV co-infection.
|
PLoS One
|
2008
|
0.88
|
|
37
|
Neisseria gonorrhoeae effectively blocks HIV-1 replication by eliciting a potent TLR9-dependent interferon-α response from plasmacytoid dendritic cells.
|
Cell Microbiol
|
2010
|
0.87
|
|
38
|
Expression of membrane drug efflux transporters in the sigmoid colon of HIV-infected and uninfected men.
|
J Clin Pharmacol
|
2013
|
0.84
|
|
39
|
T cell Activation does not drive CD4 decline in longitudinally followed HIV-infected Elite Controllers.
|
AIDS Res Ther
|
2011
|
0.84
|
|
40
|
Human endogenous retrovirus K(HML-2) Gag- and Env-specific T-cell responses are infrequently detected in HIV-1-infected subjects using standard peptide matrix-based screening.
|
Clin Vaccine Immunol
|
2011
|
0.84
|
|
41
|
Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
|
AIDS
|
2012
|
0.84
|
|
42
|
Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy.
|
HIV Clin Trials
|
2003
|
0.84
|
|
43
|
HIV viral shedding in semen: lack of correlation with systemic virus-specific CD8 responses.
|
AIDS
|
2004
|
0.82
|
|
44
|
HIV delays IFN-α production from human plasmacytoid dendritic cells and is associated with SYK phosphorylation.
|
PLoS One
|
2012
|
0.82
|
|
45
|
Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men.
|
J Acquir Immune Defic Syndr
|
2013
|
0.82
|
|
46
|
Endometrial epithelial cell response to semen from HIV-infected men during different stages of infection is distinct and can drive HIV-1-long terminal repeat.
|
AIDS
|
2012
|
0.82
|
|
47
|
Short communication: human immunodeficiency virus rebound in blood and seminal plasma following discontinuation of antiretroviral therapy.
|
AIDS Res Hum Retroviruses
|
2012
|
0.81
|
|
48
|
Impact of CMV therapy with valganciclovir on immune activation and the HIV viral load in semen and blood: an observational clinical study.
|
J Acquir Immune Defic Syndr
|
2014
|
0.80
|
|
49
|
Immunologic effectiveness of maraviroc- and raltegravir-containing regimens (R+M+) versus raltegravir-based regimens that do not include maraviroc (R+M-).
|
J Int Assoc Physicians AIDS Care (Chic)
|
2012
|
0.80
|
|
50
|
The recombinant hepatitis B surface antigen vaccine in persons with HIV: is seroconversion sufficient for long-term protection?
|
J Infect Dis
|
2012
|
0.79
|
|
51
|
Impact of antiretroviral therapy duration and intensification on isolated shedding of HIV-1 RNA in semen.
|
J Infect Dis
|
2013
|
0.79
|
|
52
|
The impact of CCL3L1 copy number in an HIV-1-infected white population.
|
AIDS
|
2010
|
0.78
|
|
53
|
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.
|
HIV Clin Trials
|
2006
|
0.78
|
|
54
|
Latent TGF-β1 is compartmentalized between blood and seminal plasma of HIV-positive men and its activation in semen is negatively correlated with viral load and immune activation.
|
Am J Reprod Immunol
|
2014
|
0.77
|
|
55
|
Characterization of cross-reactive CD8+ T-cell recognition of HLA-A2-restricted HIV-Gag (SLYNTVATL) and HCV-NS5b (ALYDVVSKL) epitopes in individuals infected with human immunodeficiency and hepatitis C viruses.
|
J Virol
|
2010
|
0.77
|
|
56
|
A case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy.
|
Antivir Ther
|
2011
|
0.77
|
|
57
|
Impact of collection method on assessment of semen HIV RNA viral load.
|
PLoS One
|
2011
|
0.77
|
|
58
|
Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection.
|
Clin Infect Dis
|
2013
|
0.77
|
|
59
|
Long-term efficacy and safety of polyalkylimide gel for the treatment of HIV-associated lipoatrophy.
|
AIDS Care
|
2009
|
0.76
|
|
60
|
Antiretroviral therapy in HIV-infected elite controllers: impact on gut immunology, microbial translocation, and biomarkers of serious non-AIDS conditions.
|
J Acquir Immune Defic Syndr
|
2014
|
0.76
|
|
61
|
Four-year follow-up of polyalkylimide gel use for the treatment of HIV-associated lipoatrophy.
|
HIV Clin Trials
|
2011
|
0.76
|
|
62
|
Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives?
|
AIDS Res Ther
|
2009
|
0.76
|
|
63
|
Impact of intensified antiretroviral therapy during early HIV infection on gut immunology and inflammatory blood biomarkers: a randomized controlled trial.
|
AIDS
|
2017
|
0.75
|
|
64
|
Short communication: HIV type 1 accumulates in influenza-specific T cells in subjects receiving seasonal vaccination in the context of effective antiretroviral therapy.
|
AIDS Res Hum Retroviruses
|
2012
|
0.75
|
|
65
|
Recognizing cognitive and psychiatric changes in the post-highly active antiretroviral therapy era.
|
Can J Infect Dis Med Microbiol
|
2012
|
0.75
|
|
66
|
Triple active antiretroviral regimen including enfuvirtide via the Biojector is effective and safe.
|
Can J Infect Dis Med Microbiol
|
2007
|
0.75
|
|
67
|
Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles.
|
HIV Clin Trials
|
2016
|
0.75
|